AGILE THERAPEUTICS INCAGRX
| Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
---|
Net loss | - | - | - | -28 | -20 | -19 | -52 | -75 | -25 |
---|
Noncash inventory reserve | - | - | - | - | - | - | - | 5 | - |
---|
Depreciation | 12,551 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
---|
Amortization | - | - | - | - | - | 0 | 0 | 0 | 0 |
---|
Loss on disposition of assets | - | - | - | - | - | - | - | - | -11 |
---|
Share-based Compensation | 1 | 3 | 3 | 4 | 4 | 2 | 3 | 3 | 2 |
---|
Paid-in-Kind Interest | - | - | - | - | - | - | 1 | 2 | 2 |
---|
Unrealized gain on warrants | -348,430 | 0 | -0 | -0 | -0 | - | - | - | -26 |
---|
Accounts receivable | - | - | - | - | - | - | 1 | 1 | 2 |
---|
Inventory | - | - | - | - | - | - | - | 6 | 0 |
---|
Prepaid expenses and other assets | 2 | 1 | -1 | -2 | -0 | 0 | 2 | 1 | -1 |
---|
Accounts payable and accrued expenses | 3 | 1 | 0 | -2 | -1 | 1 | 4 | 5 | -1 |
---|
Lease liability | - | - | - | - | - | 0 | 0 | 131,000 | 0 |
---|
Net cash used in operating activities | - | - | - | -25 | -17 | -16 | -47 | -65 | -36 |
---|
Purchases of marketable securities | - | - | - | - | - | - | 55 | - | - |
---|
Sales and maturities of marketable securities | - | - | - | - | - | - | 15 | 40 | - |
---|
Acquisition of property and equipment | 95,739 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
---|
Net cash (used in) provided by investing activities | - | - | - | -1 | -0 | -0 | -41 | 39 | -0 |
---|
Proceeds from Issuance of Preferred Stock and Preference Stock | - | - | - | - | - | - | - | - | 4 |
---|
Proceeds from Issuance Initial Public Offering | 50 | - | 38 | - | - | - | - | - | 22 |
---|
Proceeds from At-the-Market sales of common stock, net of offering costs | - | - | - | - | - | - | - | 9 | 13 |
---|
Proceeds from issuance of long-term debt | - | - | - | - | - | - | 20 | - | - |
---|
Repayments of long-term debt | - | - | - | - | - | - | - | - | 17 |
---|
Debt financing costs paid | 150,000 | 0 | 0 | - | - | - | 1 | - | - |
---|
Proceeds from Stock Options Exercised | 67,288 | 1 | 0 | 0 | - | 0 | 1 | 0 | - |
---|
Net cash provided by financing activities | - | - | - | 13 | -11 | 42 | 68 | 30 | 22 |
---|
Net (decrease) increase in cash and cash equivalents | - | - | - | - | -28 | 27 | -20 | 5 | -14 |
---|
Warrants issued in connection with long-term debt | - | - | - | - | - | - | 4 | 1 | - |
---|
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | - | - | - | - | - | - | - | 1 | - |
---|
Interest paid | - | - | - | 1 | 1 | - | 2 | 2 | 1 |
---|